Oct 13, 2008 | The Post Chronicle
Hereditary Angioedema Drug Is Approved
The U.S. Food and Drug Administration has approved for marketing the first product in the United States that protects people with hereditary angioedema.
Dyax Corp. has completed its application for federal regulatory approval for a new hereditary angioedema treatment.
“Cubist brings a wealth of clinical resources and commercial expertise in the development of a hospital-based therapy, which will serve to maximize the potential of DX-88 in the prevention of blood loss during surgery”
CAMBRIDGE, Mass. & LEXINGTON, Mass.-- --Dyax Corp. and Cubist Pharmaceuticals, Inc. via BioSpace
Read more articles in the Angioedema News Archives.
For up to the minute news, check out the Angioedema News Wire.
Want to add Angioedema News headlines to your web site? Get the widget here.
Comment?
Talk about Angioedema
Do you have something to say about Angioedema? 
Angioedema Poll
Top Stories
Most Popular
News Trends
